Dent Neurologic


IGC PHARMA (Alzheimer’s Disease with Agitation)

This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.

Inclusion Criteria:

  • 60 years of age and above
  • Diagnosis of probable Alzheimer’s Disease
  • Clinically significant agitation, must have a caregiver who can comply with required procedures

What to Expect

Participants will receive either IGC-AD1 or a placebo as an oral tincture. A placebo looks like the study drug but contains no real medicine. After 6 weeks, participants may have the opportunity to enroll in an open-label extension study, where ACP-204 will be administered (no placebo)

For more information click the link below or contact Tiffany Hoefler at or 716-961-9219

Scroll to Top